Neurimmune and Ethris plan to develop inhaled mRNA-based antibody therapy for the treatment of Covid-19

Companies expect to initiate clinical testing in 2020

03-Apr-2020 - Neurimmune AG and Ethris GmbH announced an exclusive partnership to develop mRNA-encoded, neutralizing anti-SARS-CoV-2 antibodies administered by inhalation for the treatment of Covid-19. The collaboration brings together Neurimmune’s expertise in developing human antibodies based on ...

Antibody reduces harmful brain amyloid plaques in Alzheimer's patients

01-Sep-2016 - Aducanumab, an antibody developed by the University of Zurich, has been shown to trigger a meaningful reduction of harmful beta-amyloid plaques in patients with early-stage Alzheimer's disease. These protein deposits in the brain are a classic sign of Alzheimer's disease and contribute to the ...

Biogen Idec and Neurimmune Announce Agreement on Three Neurodegenerative Disease Programs

04-Jan-2011 - Biogen Idec and Neurimmune Holding AG announced that Biogen Idec has acquired a subsidiary of Neurimmune, which includes the world-wide rights to three pre-clinical immunotherapy programs. The three programs are focused on the discovery and development of novel human antibodies that address three ...

Neurimmune Therapeutics AG Awarded the 2010 ZKB TECHNOPARK Pioneer Award

15-Apr-2010 - The ZKB TECHNOPARK® Pioneer Award, which has been sponsored by the Zürcher Kantonalbank since 2000, was presented for the 20th time at TECHNOPARK® Zurich. The award is given for technological innovations which are about to be launched on the market. This year’s award winner is Neurimmune ...

Neurimmune Therapeutics Announces Advancement of Alzheimer’s Program into Preclinical Development

19-Aug-2009 - Neurimmune Therapeutics AG announced that its lead human therapeutic antibody for Alzheimer’s disease has advanced into preclinical development, triggering milestone payments of an undisclosed amount from Biogen Idec. Neurimmune partnered with Biogen Idec for the worldwide development and ...

Biogen Idec and Neurimmunie Therapeutics announce alliance to develop treatments for Alzheimer's disease

21-Nov-2007 - Biogen Idec and Neurimmune Therapeutics AG announced they have entered into an agreement for the worldwide development and commercialization of novel, fully human antibodies for the treatment of Alzheimer's disease (AD). The alliance will focus on the development of antibodies that bind to ...